# Moleculin Biotech, Inc.

Type: Company (MBRX)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/moleculin-biotech-inc
Canonical HTML page: https://getbiobrief.com/entity/moleculin-biotech-inc

## Timeline

- **2026-08-13**: Q2 earnings released; EPS beats consensus — Company reported ($1.40) EPS versus ($1.55) consensus; shares rose $0.05 to $0.57 on 2.3x average volume
- **2026-07-17**: Weiss Ratings reiterates Sell — Restated a 'sell (e+)' rating on MBRX shares in a research note
- **2026-05-16**: Wall Street Zen downgrades MBRX — Cut its rating from 'sell' to 'strong sell' in a research note
- **2025-12**: Jane Street Group discloses new MBRX position — Acquired 22,550 shares valued at approximately $75,000 during Q4 2025, per SEC filing, representing about 1.11% of the company

## Recent coverage (1 stories)

### Moleculin's $4.06M Market Cap vs ($1.40) EPS: Pipeline Survival?
2026-08-17 00:56:41 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Clinical-stage Moleculin Biotech is now valued at just $4.06 million after a 97% collapse from its 52-week high, raising existential questions about its ability to fund development of therapies for resistant tumors and viral infections. The EPS 'beat' of ($1.40) versus ($1.55) is a paper figure — no revenue, cash balance, or clinical milestone accompanied the report.
Full story: https://getbiobrief.com/story/moleculin-4m-market-cap-eps-loss-pipeline-survival

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.